Last updated: July 12, 2026
Genentech sued Aurobindo in the District of Delaware for patent infringement tied to Aurobindo’s generic launch plans. The case sits in the Paragraph IV landscape and is procedurally anchored to Delaware’s consolidated patent docket style under Judge Richard G. Andrews (RGA).
Case at a glance (what the docket posture indicates)
| Item | Value |
|---|---|
| Court | District of Delaware |
| Caption | Genentech, Inc. v. Aurobindo Pharma Limited |
| Case No. | 1:19-cv-00078-RGA |
| Judge | Richard G. Andrews (RGA) |
| Relief sought (typical in this posture) | Permanent injunction, infringement damages, and declaratory relief tied to Orange Book-listed patents |
| Core dispute type | Patent infringement triggered by FDA-related generic/biosimilar pathway conduct and Paragraph IV notice |
What is the Genentech v. Aurobindo Pharma Limited 1:19-cv-00078-RGA lawsuit about?
The case is a patent infringement action brought by Genentech against Aurobindo in Delaware, consistent with a Hatch-Waxman dispute tied to an abbreviated approval submission and a Paragraph IV certification. In this procedural setting, the asserted patents are usually Orange Book-listed for the branded biologic/drug product at issue, and the infringement theory follows the generic product’s proposed manufacturing and proposed labeling.
Litigation function in Hatch-Waxman
- The brand owner alleges that Aurobindo’s proposed product infringes one or more asserted patents.
- Aurobindo’s counter-position typically tracks non-infringement and/or invalidity, including anticipation, obviousness, and indefiniteness arguments.
- The case timing typically determines whether the “30-month stay” blocks FDA approval and affects generic market entry dates.
Which patents were asserted in 1:19-cv-00078-RGA, and what claims do they typically cover?
The litigation record structure for this type of dispute typically includes:
- Composition-of-matter claims (active ingredient structure or critical moiety),
- Formulation claims (excipients, concentrations, buffers, lyophilized composition parameters),
- Method-of-use claims (therapeutic regimen and patient selection),
- Manufacturing process claims (cell line processes, purification steps, or formulation/manufacturing parameters).
Practical read-through for business decisions
- If the asserted estate is composition- or formulation-heavy, entry risk is highest at the “product similarity” stage.
- If it is method-of-use heavy, the label and clinical regimen language are the primary infringement levers.
- Process patents shift risk toward manufacturing/IP design around.
How does this case fit into the Orange Book and Paragraph IV framework?
This dispute is procedurally consistent with a Paragraph IV patent challenge:
- Genentech’s complaint is anchored to one or more patents listed for the relevant reference product.
- Aurobindo’s Paragraph IV notice triggers a litigation timeline and a potential regulatory stay.
- The FDA program and the litigation schedule interact, affecting the probability of launch before or after patent expiry.
Outcome levers
- Settlement terms often include timing-based launch restrictions or “carve-outs.”
- Consent judgments can lead to modified injunction scopes.
- Dismissals or summary judgment can shorten exclusivity and unlock earlier entry.
What procedural milestones and court orders matter most for risk analysis?
In Delaware Paragraph IV cases, the business-critical milestones usually include:
- Complaint filing and service,
- Patent infringement contentions and claim construction setup,
- Markman/hearing scheduling,
- Summary judgment decisions on infringement and/or validity,
- Trial scheduling and any partial verdicts,
- Injunction-related rulings,
- Settlement or voluntary dismissal (if achieved),
- Any post-judgment stay or appeal posture.
Why this matters
- Claim construction can narrow the infringement scope quickly.
- Validity rulings often determine whether settlement is economically rational.
- Interim injunctive elements affect launch-day risk and inventory planning.
How strong is Genentech’s patent estate in disputes against Aurobindo-type challengers?
Genentech’s patent strategy across its branded portfolio generally emphasizes:
- Broad foundational claims to core molecular/biologic structures,
- Dependent claims that survive design-around attempts,
- Specific formulation or process claims to create “manufacturing barriers,”
- Method-of-use claims that attach to label language and dosing regimens.
Case analysis lens
For a defendant like Aurobindo, the “strength” question usually reduces to:
- Whether the asserted claims are likely to survive construction and invalidity,
- Whether infringement is provable from Aurobindo’s described manufacturing and product parameters,
- Whether claim scope is narrow enough to allow a workable label or process design-around.
What generic entry risks exist for Aurobindo under Hatch-Waxman timing?
The litigation’s key commercial risk points include:
- Potential 30-month stay if Aurobindo’s submission is tied to Paragraph IV,
- The need to clear each asserted patent or reach settlement coverage,
- Risk of a barred launch if the asserted patents are found infringed and valid,
- Risk of market entry delays due to appeals, injunction scopes, or continued enforcement.
Design-around risk
- If Genentech’s asserted claims cover fundamental product/formulation parameters, Aurobindo’s ability to switch to a non-infringing approach may be limited.
- If only label-bound method-of-use claims are asserted, a label carve-out may reduce risk, but only if it aligns with FDA regulatory requirements and does not trigger other asserted claims.
Did Genentech and Aurobindo reach a settlement, and what does it mean for launch dates?
The settlement analysis in this litigation class is driven by:
- Whether the parties entered a consent judgment or settlement that specifies an agreed launch date,
- Whether settlement covers all asserted patents or only part of the claim set,
- Whether settlement includes “at-risk” launch triggers for non-settled patents.
Business impact framework
- Settlement that includes earlier-than-expected launch indicates lower brand-enforcement confidence or economic tradeoffs.
- Settlement that delays launch to near patent expiry suggests stronger brand patent confidence or a favorable trial posture.
What patent litigation affects market strategy for Genentech and Aurobindo post-2019?
In multi-patent cases:
- Even if some claims are knocked out, remaining patents can still block launch.
- If the case ends on procedural grounds (dismissal, stipulation), it may not fully resolve validity but can still alter commercial timelines.
- Post-judgment appeals can extend entry constraints even after partial rulings.
How does this case compare with other Genentech vs. generic defendants in Delaware?
Across Delaware Paragraph IV cases, common patterns include:
- Multiple asserted patents from an Orange Book listing,
- Early contentions tightly limiting each party’s trial theory,
- Markman-driven shifts in infringement and validity focus,
- Settlement as a common endpoint when the case is near claim construction or before trial.
Competitive landscape implication
- Other generic entrants often use these rulings to adjust their own design-around strategies and labeling plans.
- Findings on construction or invalidity can become persuasive tools in later disputes.
What is the likely regulatory endgame if Aurobindo prevails or settles?
If Aurobindo succeeds (full or partial), the endgame usually includes:
- FDA product approval and labeling aligned with carve-outs,
- Potential “at launch” risks if any remaining patents are still enforceable,
- Continued brand enforcement against later entrants or later-filed generics tied to other patents.
If Genentech prevails:
- Aurobindo’s launch is blocked for the remaining enforceable patents unless design-around or new litigation path is pursued.
Key takeaways
- Genentech’s Delaware suit (1:19-cv-00078-RGA) fits the Paragraph IV patent dispute pattern, where patent scope and construction drive infringement outcomes and launch timing.
- The economic outcome for Aurobindo depends on how many asserted patents remain enforceable after claim construction and any validity rulings.
- Any settlement or dismissal would typically translate into a specific launch window, with market entry constrained by the set of patents not carved out.
FAQs
1) What type of claims are usually asserted in Genentech Paragraph IV cases in Delaware?
Typically a mix of composition/formulation and method-of-use claims aligned to Orange Book-listed patents and the proposed generic product’s parameters and labeling.
2) How do claim construction outcomes affect generic launch risk in Hatch-Waxman suits?
Construction narrows or broadens claim elements that determine both infringement proof and validity burdens, often shifting settlement leverage before trial.
3) Does winning on validity automatically clear all patents in a multi-patent case?
Not necessarily. Brands often assert multiple patents; invalidating one can still leave others in force that block approval or trigger design-around.
4) What role do settlements play in Delaware Paragraph IV cases?
Settlements commonly specify agreed launch dates, permit labeling adjustments, and allocate whether certain patents remain contested or enforced.
5) How should companies model “at-risk” launch decisions after litigation?
They should map the remaining enforceable patents, the injunction scope, and any appeal posture that could delay or deter launch even after favorable rulings.
References
- D. Del. docket, Genentech, Inc. v. Aurobindo Pharma Limited, No. 1:19-cv-00078-RGA.
